Quick Answer
Royalty Pharma plc reported Total Assets of $19.62 billion for the year ending 2025.
- Royalty Pharma plc showed an increase of +7.7% in Total Assets from 2024 to 2025.
- This data is from Royalty Pharma plc's annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $15.69 billion | Q3 2020: $15.99 billion | Q1 2021: $15.91 billion | Q2 2021: $16.51 billion | Q3 2021: $17.73 billion | Q1 2022: $17.38 billion | Q2 2022: $17.74 billion | Q3 2022: $17.67 billion | Q1 2023: $17.07 billion | Q2 2023: $17.12 billion | Q3 2023: $15.86 billion | Q1 2024: $16.13 billion | Q2 2024: $17.66 billion | Q3 2024: $18.04 billion | Q1 2025: $17.61 billion | Q2 2025: $18.32 billion | Q3 2025: $19.35 billion.
- Over the full 7 years of available data (2019 to 2025), Royalty Pharma plc's Total Assets has grown by 57.6%.
- Historical annual values: Fiscal year 2025: $19.62 billion | Fiscal year 2024: $18.22 billion | Fiscal year 2023: $16.38 billion | Fiscal year 2022: $16.81 billion | Fiscal year 2021: $17.52 billion | Fiscal year 2020: $16.02 billion | Fiscal year 2019: $12.45 billion.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: